Weis Markets, Inc. reported its fourth‑quarter and full‑year 2025 financial results, showing a 5.0% increase in revenue to $1.30 billion for the 13‑week quarter and a 3.5% rise to $4.96 billion for the year. Net income fell 5.1% to $31.96 million in the quarter and 11.6% to $93.69 million for the year, while diluted earnings per share were $1.24 in the quarter and $3.65 for the year, both slightly below the $1.25 and $3.94 reported in 2024.
Revenue growth was driven by a 21% surge in e‑commerce sales and a notable increase in pharmacy volume, which benefited from a competitor’s exit in the market. Comparable store sales also contributed to the top‑line lift, offsetting modest headwinds in legacy product categories. The company’s record capital expenditures, including five new store openings and seven major remodels, supported the expansion of its physical footprint and the modernization of its supply‑chain operations.
Net income and EPS slipped as cost pressures and investment spending weighed on profitability. The company cited increased labor and goods costs, as well as the impact of capital‑expenditure projects, as key drivers of margin compression. Management noted that the restated financial statements—completed after correcting overstated inventory—were reflected in the reported figures, underscoring the company’s commitment to accurate financial reporting.
"Despite ongoing cautious customer spending, our Company achieved strong year‑over‑year sales growth, supported by significant price investments and record capital expenditures that enabled five new store openings and seven major remodels. We also delivered a 21% increase in e‑commerce sales while benefitting from elevated pharmacy volume following a competitor's market exit," said Jonathan H. Weis, Chairman, President, and CEO. "In 2025, long‑term investing remained a priority as we continued to support our future growth. Our store, supply‑chain and support associates helped us improve efficiencies and incorporate technologies that promote a superior customer experience. We are proud of our associates and grateful for their many contributions."
The restatement of historical financial statements, completed after identifying overstated inventory, was finalized in the 2025 annual report filed on March 12 2026. While the restatement addressed accounting controls, it also highlighted the company’s focus on transparency and accurate reporting. The earnings release did not include new forward guidance, but management’s comments emphasize continued investment in e‑commerce, pharmacy, and store modernization as key growth drivers for the coming year.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.